GlobeNewswire

2024-12-06 07:00

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

  • Teva entered into an agreement with JKI Co., Ltd. (“JKI”) established by the fund managed and operated by private equity firm J-Will Partners Co., Ltd. ("J-Will”), through which JKI will acquire Teva-Takeda
  • The agreement is aligned with Teva's Pivot to Growth strategy to focus its business
  • The expected divestment of Teva-Takeda, Teva's business venture in Japan, which includes generics products and legacy products, will allow Teva to focus on bringing its innovative medicines to the Japanese market

TEL AVIV, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Today, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that it has entered into an agreement with JKI, established by the fund managed and operated by J-Will, whereby all shares of Teva Takeda Pharma Limited and its wholly owned subsidiary Teva Takeda Yakuhin Ltd. will be transferred to JKI.

Teva recently communicated that it was open to exploring new strategic approaches in Japan, including a possible divestment of its Teva-Takeda business venture, in alignment with its Pivot to Growth strategy. The divestment will allow Teva to focus on its innovative medicines business in Japan.

Teva expects the divestiture to be completed by 1 April, 2025, subject to standard closing conditions, including obtaining required regulatory approvals. All the employees of the business venture in Japan will remain employed, subject to the terms of the agreement.

“This is another step in our Pivot to Growth strategy to focus the business,” said Mark Sabag, Executive Vice President, International Markets Commercial. “Furthermore, we are confident that this agreement with JKI will ensure the continued delivery of high-quality, affordable medicines to patients in Japan.”

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its ~37,000 employees across 58 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes of millions of patients every day. To learn more about how Teva is all in for better health, visit www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, you can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks and uncertainties relating to: our ability to successfully divest our Teva-Takeda business venture in Japan; the terms, timing, structure, benefits and costs of such divestiture and whether such divestiture will be consummated at all; the impact of any divestiture transaction on the remaining businesses of Teva in Japan and our ability to focus on our innovative business in Japan; our ability to satisfy the closing conditions to completing the divestiture of our business venture in Japan, including to obtain the required regulatory approvals; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generics medicines; and other factors discussed in our Quarterly Report on Form 10-Q for the third quarter of 2024 and in our Annual Report on Form 10-K for the year ended December 31, 2023, including in the sections captioned "Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

IR Contacts Chris Stevo+1 (339) 213-3999
  Yael Ashman+972 (3) 914 8262
  Sanjeev Sharma+1 (973) 658 2700 
PR Contacts Kelley Dougherty
Eden Klein
+1 (973) 832-2810
+972 (3) 906 2645

Primary Logo

source: Teva Pharmaceutical Industries Ltd

【你點睇?】澤連斯基與特朗普會面不歡而散,你認為美烏最終能否達成協議?英法或組「意願聯盟」,你認為歐洲有否能力促成俄烏和談?► 立即投票

人氣文章
最近7天
1
港股 | 蕭猷華:內地AI發展迅速,阿里巴巴股價看俏
2
PapaHome淘寶家具實體店22日開幕,選址尖沙咀中港城,料創100個就業機會
3
財政預算案2025 | 重點文字直播/Youtube直播(稍後送上懶人包)
4
高息定存 | 華僑銀行推新春港元定存優惠,88天或188天享3.68厘
5
高息定存 | 一周高息合集,蛇年定存金蛇起舞,1個月定存高達8厘
6
高息定存 | 一周高息合集,3個月5厘之選有邊間?6個月最高3.55厘
7
啟德體育園明天足球賽測試,4.4萬公僕參與涉逾400萬車馬費
8
高息定存 | 一周高息合集,減息預期降溫,銀行3個月最高5.68厘,6個月3.55厘
9
專訪 | 關稅戰 | 香港物流協會副會長梁庭彰:美物流商停收包裹對跨境電商打擊重大
10
【FOCUS】悟空、哪吒、DeepSeek,如何啟示香港
11
港股 | 午市前瞻 | iPhone SE難救中國市場 專家提醒比電已超買
12
大S | 台灣藝人徐熙媛因流感併發肺炎逝世,享年48歲
13
收市短打 | 楊韻銳:港股升勢有成交配合 惟留意關鍵阻力位!
14
高息定存 | 信銀國際12個月港元定存高達3.5厘
15
日入而息 | 習近平據報下周見科企領袖,證監會審視8券商孖展風控,大酒店轉蝕9億
16
彭博亞洲20大富裕家族,香港5大家族上榜,新地郭氏排名最高,無李嘉誠李兆基?
17
2025強積金整合獎賞一覽 轉供應商最多竟然可賺!?
18
民營企業座談會 | 習近平在京出席民營企業座談會
19
AI | 追捧DeepSeek,全球對沖基金棄印度投中國
20
港股 | 午市前瞻 | AI應用概念炒作有錢途 下階段部署邊隻好?
21
David Webb:因病情惡化,將有序結束個人財經網站
22
比特幣 | 亞洲時段虛擬貨幣大幅下跌,31萬人爆倉
23
AI | 蔡崇信確認阿里與蘋果合作,撰文談DeepSeek崛起帶來兩大啟示
24
譚仔 | 譚仔國際日資大股東溢價76%建議私有化今復牌,上市不足三年半
25
港股 | 蕭猷華:恒指升勢可持續?
26
美股收盤 | 美股三大指數收市報跌,道指跌近750點
27
神州經脈 | 習近平:經濟政策不會變,民企大顯身手正當其時
28
神州經脈 | 中國減持美債,螞蟻入局具身智能,70城樓價向好
29
港股 | 蕭猷華:恒指上半年目標25000點
30
隱瞞「賣殼」欺詐罪成,詹培忠判囚34個月,詹劍崙囚37個月
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

etnet榮膺「第九屆傳媒轉型大獎」四大獎項

【限時優惠$68/月】申請etnet強化版MQ手機串流報價服務 捕捉板塊輪動,提高獲利勝算

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

貨幣攻略

2025-26年度財政預算案

說說心理話

Watch Trends 2024

北上食買玩

Art Month 2024

理財秘笈

流感高峰期

山今養生智慧

輕鬆護老